ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment

Dow Jones

昨天

By Kelly Cloonan

Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.

The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.

The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.

The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.

Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.

"We are pursuing approvals across the region to fill that need," Adcock said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

January 14, 2026 11:14 ET (16:14 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2603485976"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603485976\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603485976?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 00:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603485976","market":"sh","top_or_hot":-1,"title":"ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Stock Rises on Accelerated Approvals from Saudi Regulators for Anktiva Treatment\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-01-15 00:14</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n</p>\n<p>\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n</p>\n<p>\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n</p>\n<p>\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n</p>\n<p>\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n</p>\n<p>\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 14, 2026 11:14 ET (16:14 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603485976","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603485976","pubTimestamp":1768407240,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment.The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months.The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer.The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region.Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said.\"We are pursuing approvals across the region to fill that need,\" Adcock said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"ImmunityBio股价因沙特监管机构加速批准Anktiva治疗而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of ImmunityBio gained after the company received accelerated approval from Saudi regulators for two indications for its Anktiva treatment. \n\n\n  The stock rose 6.6% to $3.01 on Wednesday. Shares are up 28% in the last 12 months. \n\n\n  The immunotherapy company said it received accelerated approval from the the Saudi Food and Drug Authority for Anktiva to treat non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. \n\n\n  The company also plans to open a regional office in Saudi Arabia to support its expansion in the Middle East and North Africa. It plans to work with Biopharma Cigalah as its commercial and distribution partner in the region. \n\n\n  Bladder and lung cancers have grown more common in the region, posing a need for further treatment options, Chief Executive Rich Adcock said. \n\n\n  \"We are pursuing approvals across the region to fill that need,\" Adcock said. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 14, 2026 11:14 ET (16:14 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}